Combined EZN-3042 and chemotherapy treatment prolongs survival of recipient mice with primary ALL. (A) Bioimaging of primary ALL on day 56 after transplantation of the EZN-3042 + VDL–treated cohort (n = 10) and the EZN-3088 + VDL–treated control group (n = 11). (B) Kaplan-Meier curves of NSG mice engrafted with LAX7R cells and treated with saline (black long dotted line), EZN-3088 (black small dotted line), or EZN-3042 (red interrupted line) as single agents or either EZN-3088 (black line) or EZN-3042 (red line) administered IP or by subcutaneous pump, respectively, in combination with VDL (V, 0.5 mg/kg/d; D, 10.5 mg/kg/d; and L, 1500 IU/kg/d) for 28 days. MST was 38 days for the saline group (n = 3), 41 days for the EZN-3088 group (n = 3), and 39 days for the EZN-3042 group (n = 3). The 69-day MST of the EZN-3088 + VDL–treated group (n = 11; IP, n = 3; subcutaneous pump, n = 8) compares to the 75-day MST of EZN-3042 + VDL–treated group (n = 10; IP, n = 3; subcutaneous pump, n = 7). P < .04.